IPA-3-loaded liposomes and methods of use thereof
Lipid-based delivery vehicles are provided. Nanoparticulate compositions typically including a p21 activated kinase (PAK) inhibitor and a lipid-based delivery vehicle are also provided. In preferred embodiments, the lipid-based delivery vehicle is a liposome, most preferably a sterically-stabilized liposome. Typically the lipid-based delivery vehicle includes one or more phospholipids, and optionally a sterol. In some embodiments, at least one of the phospholipids is PEGylated. In particular embodiments, the lipid-based delivery vehicle includes DSPC, DSPE-PEG2000, and cholesterol. In specific embodiments, the ratio of DSPC, DSPE-PEG, and cholesterol is 9:1:5. The nanoparticulate composition typically includes a PAK inhibitor, preferably a PAK-1 inhibitor such as IPA-3 or a derivative, prodrug, or pharmaceutically acceptable salt thereof. Methods of use, for example methods of treating cancer, particularly prostate and breast cancer by administering the composition to subjects in need thereof, are also provided.
1. A sterically-stabilized liposome comprising a molar ratio of 9:1:5:4 of 1, 2-distearoyl-sn-glycero-3-phosphatidylcholine (DSPC): 1, 2-distearoyl-sn-glycero-3phosphoethanolamine-N-[poly (ethyleneglycol)] (DSPE-PEG2000):cholesterol:inhibitor targeting PAK-1 activation-3 (IPA-3) (DSPC:DSPE-PEG2000:cholesterol:IPA-3).
2. A pharmaceutical composition comprising an effective amount of the liposome of claim 1 to treat cancer.
3. The liposome of claim 1 comprising a polydispersity index (PDI) of about 0.05 to about 0.139, a zeta potential of about −28.1 mV, or a combination thereof.
4. The liposome of claim 1 comprising a diameter of about 75 nm to about 500 nm.
5. A pharmaceutical composition comprising the liposome of claim 1 in an effective amount to treat cancer in a subject in need thereof for 2 to 5 days, and a pharmaceutically acceptable carrier.
6. A method of treating cancer comprising administering a subject in need thereof the pharmaceutical composition of claim 5 .
7. A method of reducing PAK activity in a subject in need thereof comprising administering the subject an effective amount of the pharmaceutical composition of claim 5 to reduce PAK expression or activity.
8. A method of treating prostate cancer comprising administering a subject with prostate cancer an effective amount of the composition of claim 2 to treat the subject for 2-5 days.
9. A method of treating cancer comprising administering to a subject with cancer the pharmaceutical composition of claim 2 .
10. The method of claim 9 , wherein the cancer is selected from prostate cancer, breast cancer, bone cancer, or lung cancer.
11. The method of claim 9 , wherein the cancer is a metastasis.
12. The method of claim 9 , wherein cells of the cancer express P21-activated kinase-1 (PAK1) at a higher level than normal cells of the same cell type.
13. The method of claim 9 , wherein the composition is administered to the subject 1 to 3 times per week.
14. The liposome of claim 1 comprising a diameter of about 100 nm to about 250 nm.
15. The liposome of claim 1 comprising a diameter of about 125 nm to about 150 nm.